SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending as investors react to a significant sell-off following disappointing revenue guidance and projections of a steep decline in the Chinese market. Community sentiment is deeply divided, with some investors viewing the price drop as a rare entry point for a long-term 'dividend aristocrat' play, while others warn of a 'value trap' due to stalled growth and ongoing concerns regarding management's turnaround strategy.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing high volatility as investors react to mixed quarterly earnings and the companys ongoing struggles with trade tariffs and a challenging housing market. While the community remains deeply divided, with many debating whether the stock is a long-term value opportunity or a failing luxury retailer, the stock continues to see significant short interest and intense speculation regarding future legal developments surrounding trade policy.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending due to the announcement of a massive multi-year AI infrastructure contract, which has sparked intense community debate regarding its low-float potential for a significant squeeze. Investors are actively discussing the stock's future, weighing the deal's long-term value against frustrations over current volume, price action, and perceived manipulation.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened community discussion and bullish sentiment following a significant stake acquisition by Bill Ackman, driving speculation about a potential turnaround and a massive short squeeze. Investors are closely monitoring key technical resistance levels while debating the impact of upcoming debt obligations and the company's long-term strategy.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune is trending as investors debate its potential for volatile, high-percentage swings characteristic of low-float Chinese IPOs, drawing comparisons to previous market runners. While some traders are aggressively positioning for a rapid squeeze fueled by lock-up dynamics, many participants are cautioning others about the significant risks associated with its history of extreme volatility and pump-and-dump patterns.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF is trending as investors seek exposure to the anticipated SpaceX IPO and broader space sector growth. While some community members are optimistic about its focus on space technology and satellite infrastructure, others are actively debating its low assets under management and comparing its potential performance and strategy to other existing space-linked investment vehicles.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense market speculation driven by recurring buyout rumors involving major technology and aerospace players like SpaceX and Amazon. Investors are actively debating the potential valuation of the company's critical spectrum assets and satellite infrastructure, fueled by anticipation of upcoming earnings and recent industry partnerships.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened retail interest as traders monitor its history of volatile, low-float runs and speculate on the potential for a short squeeze. Community discussion is heavily focused on the stock's lack of available shares to borrow, extreme cost-to-borrow fees, and comparisons to previous multi-bagger rallies, with many debating whether this represents a genuine reversal or a potential liquidity trap.

ElizaAgentic

ElizaAgentic is experiencing a surge in momentum and heightened social media activity as traders emphasize the asset's clean technical structure and bullish price continuation. The community is actively drawing parallels to broader market trends across major chains, fueling widespread speculation on its potential trajectory.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors react to the company moving its earnings release date to April Fools' Day and recent partnership announcements, fueling intense debate between bulls expecting a turnaround and bears citing management concerns. The community is actively discussing the potential impact of pending federal cannabis rescheduling and the broader influence of upcoming White House policy meetings on the sector's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best-Performing Leveraged ETFs of March 

War-driven volatility crushed global markets in March, but leveraged ETFs surged. Oil, VIX, and inverse plays dominated the winners' list.



<ul class="summary-bullets"><li>Q4 revenue also fell well short of $555.4 million average revenue projection by the analysts.&nbsp;</li><li>PLAY expects to deliver an increase in same store sales, revenue, adjusted core profit and to generate more than $100 million in free cash flow.</li><li>The company opened two new stores in the fourth quarter for a total of 11 new stores in fiscal 2025.</li></ul>Dave &amp; Buster’s (PLAY) shares garnered investors’ attention and fell 3% during Tuesday’s extended hours of trading as it reported lower fourth quarter revenue.&nbsp;PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024. It also fell well short of $555.4 million average revenue projection by the analysts.&nbsp;It also swung to loss during Q4 as it reported adjusted net loss of $12.0 million, or $0.35 per diluted share, compared with an adjusted net income of $25.3 million, or $0.66 per diluted share in the fourth quarter of fiscal 2024.The company opened two new stores in the fourth quarter for a total of 11 new stores in fiscal 2025. PLAY said that it also remodeled 16 Dave &amp; Buster’s stores in fiscal 2025, bringing the grand total to 51 recently remodeled Dave &amp; Buster’s stores since this remodel program began in the second half of fiscal 2023.It also ended the fourth quarter of fiscal 2025 with $482.9 million of liquidity, which included $16.6 million in cash and $466.3 million available under its $650.0 million revolving credit facility, net of letters of credit.&nbsp;<h2 class="st-heading-2">Outlook</h2>PLAY expects to deliver an increase in same store sales, revenue, adjusted core profit and to generate more than $100 million in free cash flow.“In 2026, we will make meaningful improvements to the business, sharpening our marketing to drive brand consideration, refining our pricing and menu architecture, launching a powerful lineup of culturally relevant new games, and implementing our refreshed remodel program,” said Tarun Lal, Chief Executive Officer.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around PLAY stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen almost 34% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around PLAY stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume. 

Dave & Buster’s Stock Falls 3% After Q4 Earnings Miss

 PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024.

Equity

PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024.


<ul class="summary-bullets"><li>The&nbsp;company&nbsp;opened nine new stores and closed five stores during fiscal 2025.</li><li>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025.</li><li>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares.</li></ul>Shares of J. Jill (JILL) slumped 26% on Tuesday after it reported a 3.1% decline in its fourth quarter net sales.&nbsp;Net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million compared to $142.8 million for the fourth quarter of fiscal 2024, it said. Analysts expected revenue of $135.5 million as per data from Stocktwits.&nbsp;JILL reported adjusted net loss per diluted share in the fourth quarter of fiscal 2025 at $0.02 compared to adjusted net income per diluted share of $0.32 in the fourth quarter of fiscal 2024.The company opened nine new stores and closed five stores during fiscal 2025, ending the year with 256 stores compared to 252 stores at the end of fiscal 2024.<h2 class="st-heading-2">Analyst Rationale</h2>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares following the company’s earnings report. The analyst told investors in a note that J.Jill delivered Q4 results "above a low bar," but "more importantly" FY26 guidance came in well below Street expectations, driven by cautious demand assumptions and incremental tariff headwinds.BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">Outlook</h2>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025. Analysts expected revenue for the quarter at $155.65 million, as per Stocktwits.&nbsp;For the full year of fiscal 2026, the company expects net sales to be flat to down 2% compared to fiscal 2025.JILL said that the outlook assumes an average 20% reciprocal tariff rate on applicable inventory received prior to February 28, 2026, an average 10% reciprocal tariff rate on applicable inventory received after February 28, 2026 through the first quarter of fiscal 2026, and an average 15% reciprocal tariff rate thereafter.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around JILL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company are down 19% so far in 2026.&nbsp;&nbsp;

BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.

J. Jill Stock Slumps 26% Today – Why Such A Selloff?

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 

<ul class="summary-bullets"><li>BlackSky stated that this contract is aimed at helping with the design and development of next-generation space intelligence.</li><li>CEO Brian O’Toole noted that these developments will enable ultra-high-resolution imaging, enhanced collection performance, and low-latency space-based communications.</li><li>BlackSky said the satellites will serve multiple roles, including acting as data storage and processing hubs and integrating with on-orbit data centers.</li></ul>BlackSky Technology Inc. (BKSY) on Tuesday announced that it has won a U.S. government contract for designing technology for Earth observation.The company stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million. BlackSky also added that it has already received an initial payment of $2 million.<a href="https://stocktwits.com/symbol/BKSY">BlackSky shares</a> were up nearly 9% in Tuesday morning’s trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">Developing Next-Gen Space Intelligence</h2>BlackSky stated that this contract is aimed at helping with the design and development of next-generation space intelligence. It added that the capabilities and mission applications this project addresses are distinct from those addressed by current Gen-2 and Gen-3 monitoring systems and the company’s future AROS broad-area search system.“We will leverage the unique, highly scalable core technology of Gen-3 into every incremental advancement along our roadmap, looking at the AROS broad area search system as the next step into the more expansive very large-aperture optical imagery capabilities covered by this contract,” said BlackSky CEO Brian O’Toole.He added that these developments will enable ultra-high-resolution imaging, enhanced collection performance, and low-latency space-based communications.The company expects the contract to enable expanded applications in high-cadence Earth monitoring and tracking objects across low Earth, geostationary, and cis-lunar orbits.<h2 class="st-heading-2">Satellites With Multi-Role Capabilities</h2>BlackSky noted that the satellites that will be developed under this contract will serve multiple roles. This includes operating as a data storage and processing hub and being compatible with on-orbit data centers.The company noted that this is an indefinite-delivery, indefinite-quantity contract for a multi-year period.BlackSky is a Herndon, Virginia-based company that provides real-time space intelligence with on-demand imagery, analytics, and high-frequency monitoring of critical global assets and events.<a href="https://stocktwits.com/symbol/BKSY">BKSY stock</a> is up 24% year-to-date and 202% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 15% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 22%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-sold-apple-shares-too-soon-berkshire/cZEPvVFRIVi">Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BlackSky Technology logo is seen displayed on a smartphone screen.

BKSY Stock Is Rising Today – This Government Deal Could Be A Turning Point

BlackSky Technology (BKSY) stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million.

The company stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million.

<ul class="summary-bullets"><li>In connection with the transaction, Repay has received a debt commitment letter from Truist Bank for a $500 million term loan, along with a $100 million undrawn revolving credit facility.&nbsp;</li><li>RPAY expects the transaction to close in the second quarter of 2026.</li><li>It expects the transaction to unlock additional value with expected revenue opportunities of approximately $5+ million by 2028.</li></ul>Repay Holdings (RPAY), a provider of integrated payment processing solutions, on Monday announced a definitive agreement to acquire Kubra Data Transfer for approximately $372 million in an all-cash transaction.&nbsp;The company said that the acquisition will be financed with a combination of cash on hand and debt financing.Shares in the company fell nearly 1% during extended hours of trading on Monday.&nbsp;<h2 class="st-heading-2">More Details</h2>In connection with the transaction, RPAY has received a debt commitment letter from Truist Bank for a $500 million term loan, along with a $100 million undrawn revolving credit facility.&nbsp;Repay said that the deal is expected to generate approximately $15+ million of annual run-rate costs synergies and approximately $5+ million of technology savings over the next three years through combining operations, platform consolidation, and other scale efficiencies.&nbsp;“Today’s announcement advances REPAY on our transformational journey to become a leading bill payment provider. The combination brings together highly complementary go-to-market approaches, creating robust opportunities to enhance growth,” said John Morris, Co-Founder and Chief Executive Officer of Repay.The transaction is subject to regulatory approvals in the U.S. and Canada and certain customary closing conditions. The company expects the transaction to close in the second quarter of 2026.<h2 class="st-heading-2">Expected Gains</h2>Repay expects the transaction to unlock additional value with expected revenue opportunities of approximately $5+ million by 2028 as RPAY benefits from offering bill presentment, communications services, a payment engine, and core processing solutions across all clients.It also expects free cash flow accretion of 25% by 2028.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RPAY stock trended in ‘neutral’ territory amid ‘normal’ message volume.&nbsp;Shares in the company have fallen around 15% so far this year.

Retail sentiment around RPAY stock trended in ‘neutral’ territory amid ‘normal’ message volume. 

Repay Stock Falls As $372M Deal Fails To Impress Investors

The company said that the acquisition will be financed with a combination of cash on hand and debt financing.

<ul class="summary-bullets"><li>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC&nbsp;reported, citing data from Argus.&nbsp;</li><li>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28.</li></ul>JetBlue Airways (JBLU) is reportedly raising bag fees for its flyers as rising fuel prices due to the ongoing Iran war begin to&nbsp;weigh on the company.“As we experience rising operating costs, we regularly evaluate how to manage those costs while keeping base fares competitive and continuing to invest in the experience our customers value,” JetBlue said in a statement to CNBC.Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC reported, citing data from Argus.&nbsp;Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28. The recent rise in checked bag fees is the latest indication that airlines are passing higher fuel costs onto American travelers. After labor, jet fuel is the largest expense for airlines.<h2 class="st-heading-2">Rising Fuel Prices&nbsp;</h2>Crude oil jumped on Monday and stayed well above $100 a barrel mark, signalling a prolonged Iran war.&nbsp;Benchmark U.S. oil futures gained $3.24 a barrel Monday to settle at $102.88, their first close above $100 since 2022 when Russia invaded Ukraine and rattled energy markets, as per Wall Street Journal.&nbsp; Brent crude futures for May delivery were as high as $116 Monday.&nbsp;The United States Oil Fund ETF (USO) closed 4.5% higher on Monday, while the ProShares Ultra Bloomberg Crude Oil ETF (UCO) ended the day 1.7% higher.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around JBLU&nbsp;stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen around 10% so far this year.&nbsp;

JetBlue Airbus A321neo passenger aircraft spotted departing from the runway of Amsterdam Schiphol Airport in the Netherlands on April 10, 2025.

JetBlue Airways Reportedly Raises Baggage Fees As Rising Fuel Costs Bite

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 

<ul class="summary-bullets"><li>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging.</li><li>The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.</li><li>Viridian stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter of 2026.</li></ul>Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VRDN">Viridian Therapeutics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Did The Trial Reveal?</h2>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging. The study also tested a different dosing schedule (every 8 weeks) versus placebo and examined other important outcomes.The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.However, Elegrobart showed only a slight improvement over placebo in the Clinical Activity Score (CAS), a measure of inflammation and disease activity.Viridian’s results showed that the CAS reduction to 0 or 1 was 57% in the four-week regimen and 69% in the eight-week regimen, compared with 50% in the placebo group.The company said that all complaints of adverse events in both regimens were reports of tinnitus, none of which were associated with hearing reduction.<h2 class="st-heading-2">Viridian Says Elegrobart On Track For BLA Submission In 2027</h2>The company stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026.Following this, Viridian plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. A BLA is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking for approval to sell a biologic drug.<a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 12% year-to-date, but up 87% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 40% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 19%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roma-stock-soars-100m-share-repurchase-program/cZERVIhRIZs">ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

<ul class="summary-bullets"><li>The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval.</li><li>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company.</li><li>LifeSci Capital added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval.</li></ul>&nbsp;Shares of Rocket Pharmaceuticals Inc. (RCKT) dropped 22% on Friday after the company announced U.S. Food and Drug Administration's approval for its drug in the treatment of an inherited pediatric disorder, a sell-off that Wall Street dismissed as unjustified.Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, inherited pediatric immunodeficiency characterized by recurrent, severe infections.The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval. The voucher is designed to encourage the development of therapies for rare pediatric disease<h2 class="st-heading-2">Wall Street Weighs In</h2>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company, which the firm believes reflects management's strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket's balance sheet, the analyst told investors in a research note. The firm added that it does not see the negative stock price reaction as justified.LifeSci Capital analyst Patrick Dolezal also reiterated an ‘Outperform’ rating and $9 price target on Rocket Pharmaceuticals. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100 million to $200 million. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company's cardiac gene-therapy pipeline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around RCKT stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-model-y-3-deliveries-critical-as-model-s-x-approach-retirement-says-analyst/cZ3HJsGRIm9">Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.

<ul class="summary-bullets"><li>On Stocktwits, retail chatter jumped about 25% over the past day, with message volume going from ‘normal’ to ‘high’ levels in the time frame.&nbsp;</li><li>Earlier this month, Eastman Kodak reported its fourth-quarter (Q4) 2025 earnings results, posting quarterly revenues of $290 million, a growth of 9%.</li><li>Meanwhile, the company also reduced its annual interest expense by approximately $40 million in FY25, strengthening its balance sheet.</li></ul>Shares of Eastman Kodak Co. (KODK), or Kodak as it is commonly referred to, surged more than 12% on Friday, briefly breaching the $10-mark for the first time since June 2021.The iconic American photography company garnered significant attention among retail traders for the milestone, with some cheering the ‘Kodak’ moment.On Stocktwits, retail chatter jumped about 25% over the past day, with message volume going from ‘normal’ to ‘high’ levels in the time frame.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260327_105336760_png_30e5326fee.webp" alt="koyfin_20260327_105336760.png" width="2400" height="1240"><figcaption>KODK stock price over 5 years | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">&nbsp;</h2><h2 class="st-heading-2">What’s Retail Saying?</h2>Retail sentiment around KODK shares was ‘extremely bullish’ over the past 24 hours.One user touted the share price jump as a ‘Kodak moment’, using a term from the company’s successful advertising campaign.<stembedurl>https://stocktwits.com/DocPharm/message/648774392</stembedurl>&nbsp;Another bullish user cheered the company’s share price ascending to its ‘fair value.’<stembedurl>https://stocktwits.com/Lizzie1/message/648768482</stembedurl>&nbsp;A third user commented on the company’s shares climbing in a down market, while also noting Kodak’s value and strong balance sheet.<stembedurl>https://stocktwits.com/ChicagoMan/message/648637855</stembedurl>&nbsp;A fourth user said KODK shares were ‘still cheap’ despite the company’s recent financial improvement.<stembedurl>https://stocktwits.com/ChicagoMan/message/648768307</stembedurl><h2 class="st-heading-2">&nbsp;</h2><h2 class="st-heading-2">Financial Snapshot</h2>Earlier this month, Eastman Kodak reported its fourth-quarter (Q4) 2025 earnings results, posting quarterly revenues of $290 million, a growth of 9%. The company also posted operational earnings before interest, tax, depreciation, and amortization of $22 million, an increase of 144%.Meanwhile, the company also reduced its annual interest expense by approximately $40 million in FY25, with management adding that Kodak now has a “stronger balance sheet than we’ve had in years.” The company had a cash balance of $337 million as of Dec. 31, 2025, an increase of $136 million from Dec. 31, 2024, with management noting that the company now had more cash than debt.<a href="https://stocktwits.com/symbol/KODK">KODK stock</a> has risen more than 50% in the past year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/wyfi-stock-tumbles-after-earnings-miss/cZ3HJWFRImB">WYFI Stock Tumbles Nearly 10% After Q4 Earnings Miss — What's Wall Street's Take?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

KODK Stock Crosses $10-Mark For First Time In Nearly 5 Years — Retail Cheers 'Kodak Moment'

Eastman Kodak shares surged more than 12% on Friday, garnering significant attention from retail investors.

iShares Trust - iShares Russell 2000 ETF

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Stocktwits

Stocktwits Polls

iShares Russell 2000 ETF

Small caps are seeing intense momentum with significant gains as traders speculate on potential breakout levels above $250.

Discussions center on how presidential statements and middle east stability are directly influencing index volatility and market sentiment.

Market participants are weighing high mortgage rates and rising employment data against bullish price action and retail sales growth.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF